Referring to a piridino - pyridinone Derivative of formula (i), wherein R1 is H or c1-c4 alkyl R2 is - (CH2) n - B b is c3-c5 cycloalkyl or c1-c4 alkyl or alkoxy optionally substituted with F C1 - C4 n is an integer of 0 OR 1 to 4 y, Z, V, and W are CH, a carbon Atom replaced with R7, among others R7 is c1-c4 alkyl or Halogen R3 and R4 are h, c1-c4 alkyl,Among others, M and an integer from 1 to 4 h R5 or R6 is c1-c4 alkyl n - L - (CH2) n is 0, 1, 2 or 3 l is an aryl 6 carbon ATOMS, a heterocycle 6 or 6 members with a heteroatom selected from N or, among others.Preferred compounds are: {2 - [7 - amino - 4 - 8 - 6 - (ethyl) - 1H imidazole - 2 - oxo - il) - 5 - 5.8 - dihydro - [1,8] naftiridin - il - 2} - N - phenyl] pyridin-2-yl - acetamide, 2 - {6 - [7 - Amino - 8 - 6 - (ethyl) - 1H imidazole - 2 - oxo - il) - 5 - 5.8 - dihydro - [1,8] naftiridin - il - 2 -] pyridin-3-yl) - (pyridin-2-yl - acetamide, {[2 - 4 - 7 - amino - 8 - 6 - (ethyl) - 1H imidazole Il - 2 - oxo -) - 5 - [5,8 dihydro - 1,8] naftiridin IL - 2 -] - phenyl) - N - (4 - 3 - Methyl Cyclopropyl - (-) - acetamide, among others. It also relates to a preparation method and a Pharmaceutical composition.These compounds are inhibitors of the kinase activity of the receptor ligands pdgfs (growth factors derived from platelets) and \/ or receptor ligand FLT3 (FMS like tyrosine kinase receptor and are useful in the treatment of cancer, Vascular Disease, Among otherREFERIDA A UN DERIVADO DE PIRIDINO-PIRIDINONA DE FORMULA (I), DONDE R1 ES H O ALQUILO C1-C4 R2 ES -(CH2)n-B B ES CICLOALQUILO C3-C5 O ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDOS CON F O ALCOXI C1-C4 n ES 0 O UN ENTERO DE 1 A 4 Y, Z, V Y W SON CH, UN ATOMO DE CARBONO SUSTITUIDO CON R7, ENTRE OTROS R7 ES ALQUILO C1-C4 O HALOGENO R3 Y R4 SON H, ALQUILO C1-C4, ENTRE OTROS m E UN ENTERO DE 1 A 4 R5 ES H O ALQUILO C1-C4 R6 ES -(CH2)n-L n ES 0, 1, 2 O 3 L ES UN ARILO DE 6 ATOMOS DE CARBONO, UN HETEROCICLO DE 6 O 6 MIEMBROS CON UN HETEROATOMO SELECCIONADO DE N U O
